Study details
Enrolling now
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT IDNCT05039801ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
54
Study length
about 4.7 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing a treatment called IACS-6274, possibly with bevacizumab and paclitaxel, to see if it's safe and tolerable in people with advanced solid tumors. The goal is to find the highest dose that can be given safely.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Bevacizumab
- 2.Take Capivasertib
- 3.Take Glutaminase-1 Inhibitor IACS-6274
- +1 more
PhasePhase 1
DrugBevacizumab
Routeinfusion
Primary goalIncidence of adverse events (AEs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
bevacizumab, capivasertib, paclitaxel (Taxane chemotherapy; stabilizes microtubules)
Drug routes
infusion, oral (Oral Tablet), injection, intravenous
Endpoints
Primary: Incidence of adverse events (AEs)
Body systems
Oncology